Literature DB >> 3129422

Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.

R J Kaufman1, L C Wasley, A J Dorner.   

Abstract

The synthesis, processing, and secretion of factor VIII expressed from heterologous genes introduced into Chinese hamster ovary cells has been studied. The results show factor VIII to be synthesized as a primary translation product of approximately 230 kDa that can be detected in the lumen of the endoplasmic reticulum. In this compartment, the majority of the factor VIII is in a complex with a resident protein of the endoplasmic reticulum, binding protein, and may never appear in the medium. Some factor VIII transits the endoplasmic reticulum to the Golgi apparatus, where it is cleaved to generate the mature heavy and light chains. In the absence of von Willebrand factor in the medium, the secreted heavy and light chains are unassociated and subsequently degraded. In the presence of von Willebrand factor in the medium, the heavy and light chains are secreted as a stable complex and activity accumulates linearly with time. The utilization and complexity of asparagine-linked carbohydrate present on the secreted recombinant-derived factor VIII and human plasma-derived factor VIII were compared and found to be very similar. In both cases, the asparagine-linked carbohydrate moieties on the heavy chain are primarily of the hybrid or complex-type. In contrast, the factor VIII from both sources contains a high-mannose type of asparagine-linked carbohydrate on the light chain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129422

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  83 in total

1.  Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.

Authors:  S Lethagen; E Berntorp; I M Nilsson
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

2.  Effect of transmembrane pressure on Factor VIII yield in ATF perfusion culture for the production of recombinant human Factor VIII co-expressed with von Willebrand factor.

Authors:  Seung-Chul Kim; Sora An; Hyun-Ki Kim; Beom-Soo Park; Kyu-Heum Na; Byung-Gee Kim
Journal:  Cytotechnology       Date:  2015-10-13       Impact factor: 2.058

3.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

4.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

5.  Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.

Authors:  Puneet Gaitonde; Aaron Peng; Robert M Straubinger; Richard B Bankert; Sathy V Balu-Iyer
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

Review 6.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

7.  Stable expression of recombinant human coagulation factor XIII in protein-free suspension culture of Chinese hamster ovary cells.

Authors:  B H Chun; W G Bang; Y K Park; S K Woo
Journal:  Cytotechnology       Date:  2001-11       Impact factor: 2.058

8.  Stable expression in Chinese hamster ovary cells of a homogeneous recombinant active fragment of human platelet glycoprotein Ib alpha.

Authors:  B Schumpp-Vonach; G Kresbach; E J Schlaeger; B Steiner
Journal:  Cytotechnology       Date:  1995       Impact factor: 2.058

9.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

10.  In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection.

Authors:  J A Schroeder; Y Chen; J Fang; D A Wilcox; Q Shi
Journal:  J Thromb Haemost       Date:  2014-07-17       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.